Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Cytogenetic risk factors do not appear to affect survival outcomes following first-line ibrutinib for CLL/SLL, real-world survival data suggest. | Image credit: Saiful52 - stock.adobe.com
First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

June 13th 2025

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers. | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

While improvements were seen in non-relapse mortality in CLL throughout the decade, the researchers observed no differences in overall survival or progression-free survival. | Image credit: LASZLO - stock.adobe.com
New Era of CLL Treatments Brings Changes to Use of HSCT

June 9th 2025

The overall response rate with first-line zanubrutinib for CLL reached 97.3%, with 18.2% of patients experiencing complete response or complete response with incomplete hematologic recovery. | Image Credit: jarun011 - stock.adobe.com
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial

June 6th 2025

More News

Older woman fatigue headache depression | Image Credit: © fizkes - stock.adobe.com
April 12th 2024

Nonpharmacological Approaches Lead to Significant Alleviation of CLL-Associated Fatigue

Jared Kaltwasser
Investigators said both reflexology and acupressure led to similar improvement in patients after 4 weeks.
White blood cells from leukemia | Image Credit: SebastianKaulitzki - stock.adobe.com
April 9th 2024

Venetoclax Monotherapy Leads to Durable Responses in Relapsed, Refractory CLL

Jared Kaltwasser
The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
Broken arm in cast | Image credit: Thinapob - stock.adobe.com
April 5th 2024

Several Factors—but Not Osteoporosis—Increase Risk of Fractures in People With CLL

Jared Kaltwasser
Most fragility fractures experienced by people with chronic lymphocytic leukemia (CLL) are vertebral, the study found.
Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL
April 3rd 2024

Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL

Jared Kaltwasser
Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.
Gene mutation | Image Credit: © Ilya-stock.adobe.com.jpeg
March 30th 2024

Review Chronicles Advancing Insights Into Epigenetic Alterations in Chronic Lymphocytic Leukemia

Luke Halpern
Studies of DNA methylation, RNA methylation, and histone modification revealed important information about the pathology of chronic lymphocytic leukemia and treatment potential.
Lymphoma graphic| Image Credit: MP Studio - stock.adobe.com
March 27th 2024

Study Supports Use of EORTC Item Library to Assess Lymphoma Symptoms

Luke Halpern
Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.
Abstract concept of scientific research | Image Credit: kras99 - stock.adobe.com
March 23rd 2024

Review Outlines Management of Patients Receiving Venetoclax for CLL

Jared Kaltwasser
Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.
Chronic lymphocytic leukemia | Image Credit: momius - stock.adobe.com
March 20th 2024

Quest to Advance CLL Therapy Operating on Multiple Fronts

Jared Kaltwasser
There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.
Bioinformatics and Health Informatics Concept Medical and Informatics Icons on Technology Background | Image credit: ArtemisDiana - stock.adobe.com
March 16th 2024

Genomics, Transcriptomics, and Epigenomics Utilized to Better Understand Chemoimmunotherapy Resistance in CLL

Luke Halpern
Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL).
Doctor holding a test blood sample tube with leukemia test on the background of medical test tubes with analyzes | Image Credit: syhin_stas stock.adobe.com
March 13th 2024

Molecular Mapping of CLL and Richter Syndrome Offers Crucial Insights

Luke Halpern
This new analysis provides an optimistic outlook on the future of chronic lymphocytic leukemia (CLL) treatment and discoveries into the background behind CLL transformation into Richter syndrome.
Older man with cough and cold | Image Credit: © sebra - stock.adobe.com
March 8th 2024

Case Report: COVID-19 Risk in CLL Could Be Exacerbated by Hypogammaglobulinemia

Jared Kaltwasser
The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery.
Man scratching a bug bite | Image credit: Oporty786 - stock.adobe.com
March 6th 2024

Case Report Shows Dupilumab Effective at Controlling Exaggerated Insect-Bite Response in Setting of CLL

Jared Kaltwasser
A patient with chronic lymphocytic leukemia (CLL) who experience persistent exaggerated responses to insect bites was successfully treated with dupilumab.
Patient and doctor | Image Credit: © DragonImages - stock.adobe.com
February 29th 2024

Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL

Luke Halpern
In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.
Cancer cell and lymphocytes | Image credit: Christoph Burgstedt-stock.adobe.com
February 28th 2024

CLL Cells Found to Secrete IL-9, Hindering Cytotoxic T-Cell Function

Jared Kaltwasser
Investigators say the findings could lead to new therapeutic targets.
Medication Management | Image Credit: © siripimon2525 - stock.adobe.com
February 24th 2024

Discontinuation of Ibrutinib Is Common in Older Patients With CLL, Study Finds

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.
Cancer care representation | Image credit: Nikki Zalewski - stock.adobe.com
February 19th 2024

Access to Cancer Care Alleviates Racial Disparities in CLL/SLL

Gwen Mergian
No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.
Social Determinants of Health - STOATPHOTO - stock.adobe.com
February 16th 2024

Social Deprivation Independently Impacts Outcomes in Patients With Chronic Lymphocytic Leukemia

Luke Halpern
The study was the first of its kind to analyze social deprivation among CLL patients and observe the underlying reasons behind their clinical outcomes.
Lung imaging | Image credit: as-artmedia - stock.adobe.com
February 14th 2024

Mass-Like Opacities on Imaging Linked With LPI in CLL

Jared Kaltwasser
Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found.
Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma
February 11th 2024

Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma

Rose McNulty
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.
Leukemia test against a background of medical test tubes | Image credit: syhin_stas - stock.adobe.com
February 9th 2024

Analysis: More Than Half of CLL/SLL Cases Diagnosed After 2018 Received Targeted Therapy

Jared Kaltwasser
The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing.
Questionnaire | Image credit: Richelle - stock.adobe.com
February 6th 2024

Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL

Jared Kaltwasser
Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.
leukemia disease concept - vector illustration Image credit: chrupka - stock.adobe.com
February 4th 2024

Active Hexose-Correlated Compound Shows Effectiveness in CLL

Luke Halpern
Efficacy against chronic lymphocytic leukemia (CLL) was seen when tested as both a single agent and in combination with antitumor antibody.
Ann LaCasce, MD, MMSc
February 2nd 2024

Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape

Rose McNulty
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.
Chronic lymphocytic leukemia cells in blood flow-isometric view | Image credit: LASZLO - stock.adobe.com
January 26th 2024

In CLL, BTK-Inhibitor Resistance Remains a Confounding Problem

Jared Kaltwasser
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).
Chronic lymphocytic leukemia | Image credit: momius - stock.adobe.com
January 23rd 2024

Study: CLL Therapies Cannot Overcome Increased Infection, Malignancy Risk

Jared Kaltwasser
A new report compared the blood immune repertoires of patients with chronic lymphocytic leukemia (CLL) who received chemoimmunotherapy and those who received ibrutinib.
SAP logo | image credit: AJMC
January 20th 2024

ASH Abstracts Showcase Effective Treatments for MM, CLL, FL

Skylar Jeremias
Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Cancer treatment, doctor supporting patient | Image credit: catalin - stock.adobe.com
January 19th 2024

Real-World Study Confirms Efficacy of Venetoclax Alone, After BTKi Therapy in CLL

Skylar Jeremias
Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).
EBO logo
January 17th 2024

Data Reveal Racial, SDOH Factors Linked to OS Differences in CLL

Interview by Mary Caffrey
Chronic lymphocytic leukemia - LASZLO - stock.adobe.com
January 12th 2024

Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL

Rose McNulty
A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Chronic lymphocytic leukemia in blood | Image credit: LASZLO - stock.adobe.com
January 10th 2024

Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups

Rose McNulty
Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo